Search results
Results from the WOW.Com Content Network
Spravato bought in sales of $780 million for the first nine months of 2024. MDD is one of the most common mental health disorders in the U.S., according to the National Institutes of Health. About ...
Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [10] [12] is the S(+) enantiomer of ketamine. [ 5 ] [ 13 ] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression .
In neuroscience, Spravato growth of 45.3% continues to be driven by increased physician and patient demand. As Joaquin mentioned, Spravato has exceeded $1 billion in annual sales for the first time.
Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand name or generic drugs. [1] The REMS program was formalized in 2007.
An enantiomer of ketamine – esketamine commercially sold as Spravato – was approved as an antidepressant by the European Medicines Agency in 2019. [63] Esketamine was approved as a nasal spray for treatment-resistant depression in the United States [64] and elsewhere in 2019 (see Esketamine and Depression). The Canadian Network for Mood and ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]
Phil Lucas, a 32-year-old Suboxone patient, said he tried local NA meetings but no longer attends. “They acted like I was still a heroin addict basically,” he said, adding that people at the meetings kept asking him when he was going to get sober. Diana Sholler, 43, another Suboxone patient in Northern Kentucky, attends local AA meetings.